After having 17 melanoma spots removed, ‘Real Housewives of Beverly Hills’ alum Teddi Mellencamp was diagnosed with multiple ...

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

The US Fire Administration reports that firefighters are 14 percent more likely to die of cancer compared to the general ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...